Comparing Healthcare Utilization and Cost in Empagliflozin versus GLP-1RA Initiators with Type 2 Diabetes without Established Cardiovascular Disease

被引：0
|
作者：
Htoo, Phyo T. [1 ,2 ]
Tesfaye, Helen [1 ]
DiCesare, Elyse C. [2 ,3 ]
Wexler, Deborah J. [4 ]
Schneeweiss, Sebastian [5 ]
Glynn, Robert [5 ]
Shay, Christina [6 ]
Schmedt, Niklas [6 ]
Koeneman, Lisette [6 ]
Paik, Julie M. [1 ]
Patorno, Elisabetta [1 ]
机构：
[1] Brigham & Womens Hosp, Boston, MA USA
[2] Harvard Med Sch, Boston, MA USA
[3] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA USA
[4] Massachusetts Gen Hosp, Boston, MA USA
[5] Harvard Med Sch, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, Boston, MA USA
[6] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2024年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1285
引用
收藏
页码：580 / 580
页数：1
相关论文
共 50 条
  • [21] Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes
    Singhal, Mukul
    Unni, Sudhir
    Schauerhamer, Marisa
    Nguyen, Hiep
    Hurd, Jeff
    McAdam-Marx, Carrie
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (03): : 267 - 275
  • [22] Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece
    Gourzoulidis, George
    Tzanetakos, Charalampos
    Ioannidis, Ioannis
    Tsimihodimos, Vasilis
    Diogo, Viana
    Karpouzos, George
    Papageorgiou, Giannis
    Kourlaba, Georgia
    CLINICAL DRUG INVESTIGATION, 2021, 41 (04) : 371 - 380
  • [23] Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece
    George Gourzoulidis
    Charalampos Tzanetakos
    Ioannis Ioannidis
    Vasilis Tsimihodimos
    Viana Diogo
    George Karpouzos
    Giannis Papageorgiou
    Georgia Kourlaba
    Clinical Drug Investigation, 2021, 41 : 371 - 380
  • [24] Comparing Cardiovascular Benefits between GLP-1RA and SGLT2i as an Add-On to Metformin among US Adults with Type 2 Diabetes (T2D)
    Deremer, Christina E.
    Guo, Jingchuan
    Vouri, Scott M.
    Haller, Michael J.
    Donahoo, William T.
    Winterstein, Almut G.
    Shao, Hui
    DIABETES, 2021, 70
  • [25] Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease
    Monteiro, Pedro
    Aguiar, Carlos
    Matos, Pedro
    Silva-Nunes, Jose
    Birne, Rita
    Branco, Patricia
    Calado, Joaquim
    Melo, Miguel
    Polonia, Jorge
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2019, 38 (10) : 721 - 735
  • [26] Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis
    Lisco, Giuseppe
    De Tullio, Anna
    Disoteo, Olga
    De Geronimo, Vincenzo
    Piazzolla, Giuseppina
    De Pergola, Giovanni
    Giagulli, Vito Angelo
    Jirillo, Emilio
    Guastamacchia, Edoardo
    Sabba, Carlo
    Triggiani, Vincenzo
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [27] Eliminating exogenous insulin therapy in patients with type 2 diabetes by duodenal ablation and GLP-1RA decreases risk scores for cardiovascular events
    Meiring, S.
    Busch, C. B. E.
    van Baar, A. C. G.
    Hemke, R.
    Holleman, F.
    Nieuwdorp, M.
    Bergman, J. J. G. H. M.
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [28] Is the steady-state concentration, duration of action, or molecular weight of GLP-1RA associated with cardiovascular and renal outcomes in type 2 diabetes?
    Bai, Shuzhen
    Lin, Chu
    Jiao, Ruoyang
    Cai, Xiaoling
    Hu, Suiyuan
    Lv, Fang
    Yang, Wenjia
    Zhu, Xingyun
    Ji, Linong
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2023, 109 : 79 - 88
  • [29] Eliminating exogenous insulin therapy in patients with type 2 diabetes by duodenal ablation and GLP-1RA decreases risk scores for cardiovascular events
    S. Meiring
    C. B. E. Busch
    A. C. G. van Baar
    R. Hemke
    F. Holleman
    M. Nieuwdorp
    J. J. G. H. M. Bergman
    Cardiovascular Diabetology, 21
  • [30] Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
    Wanner, Christoph
    Lachin, John M.
    Inzucchi, Silvio E.
    Fitchett, David
    Mattheus, Michaela
    George, Jyothis
    Woerle, Hans J.
    Broedl, Uli C.
    von Eynatten, Maximilian
    Zinman, Bernard
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    CIRCULATION, 2018, 137 (02) : 119 - 129
12345